Motilal Oswal's research report on Procter and Gamble Hygiene and Health Care
PGHH reported sales growth of 12.6% in 4QFY23 (June year-end), higher than our exception, driven by premiumization and productivity interventions. The company beat our EBITDA/PBT/PAT estimates, as adspends were significantly lower than our expectation at 6.3% of sales (after jumping to 12.1% of sales in 3QFY23). While we remain positive on the long-term growth potential of the sanitary napkin and healthcare business, the uncertain pace of recovery and challenging valuations of ~65xFY24E EPS/~53xFY25E EPS lead us to maintain our Neutral rating.
Outlook
Nevertheless, the uncertain pace of sales and earnings recovery and expensive valuations of ~65xFY24E EPS/~53xFY25E EPS lead us to maintain our Neutral rating. We value the stock at 55x Mar’25E EPS, arriving at a TP of INR16,940.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Procter & Gamble Hygiene & Health Care - 29 -08 - 2023 - khan
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
